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Abstract 
Background: The etiology of autism spectrum disorders (ASD) is very heterogeneous. Mitochondrial dysfunction 
has been described in ASD; however, primary mitochondrial disease has been genetically proven in a small subset 
of patients. The main goal of the present study was to investigate correlations between mitochondrial DNA (mtDNA) 
changes and alterations of genes associated with mtDNA maintenance or ASD.
Methods: Sixty patients with ASD and sixty healthy individuals were screened for common mtDNA mutations. Next 
generation sequencing was performed on patients with major mtDNA deletions (mtdel-ASD) using two gene panels 
to investigate nuclear genes that are associated with ASD or are responsible for mtDNA maintenance. Cohorts of 
healthy controls, ASD patients without mtDNA alterations, and patients with mitochondrial disorders (non-ASD) har-
bouring mtDNA deletions served as comparison groups.
Results: MtDNA deletions were confirmed in 16.6% (10/60) of patients with ASD (mtdel-ASD). In 90% of this mtdel-
ASD children we found rare SNVs in ASD-associated genes (one of those was pathogenic). In the intergenomic panel 
of this cohort one likely pathogenic variant was present. In patients with mitochondrial disease in genes responsible 
for mtDNA maintenance pathogenic mutations and variants of uncertain significance (VUS) were detected more 
frequently than those found in patients from the mtdel-ASD or other comparison groups. In healthy controls and in 
patients without a mtDNA deletion, only VUS were detected in both panel.
Conclusions: MtDNA alterations are more common in patients with ASD than in control individuals. MtDNA dele-
tions are not isolated genetic alterations found in ASD; they coexist either with other ASD-associated genetic risk 
factors or with alterations in genes responsible for intergenomic communication. These findings indicate that mito-
chondrial dysfunction is not rare in ASD. The occurring mtDNA deletions in ASD may be mostly a consequence of the 
alterations of the causative culprit genes for autism or genes responsible for mtDNA maintenance, or because of the 
harmful effect of environmental factors.
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Background
In recent years, the number of patients diagnosed with 
autism spectrum disorders (ASD) has increased with 
current studies reporting a prevalence of 1% [1]. ASD 
shows extreme clinical heterogeneity; however, the diag-
nosis of ASD according to the Diagnostic and Statistical 
Manual of Mental Disorders (5th edition) is based on def-
icits in two areas—social communication and restricted, 
repetitive behaviour or interests. The patient must have 
deficits in both areas, and symptoms must be present 
from early childhood [2]. The genetic architecture of ASD 
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is very diverse consisting of a variety of genetic altera-
tions, such as chromosomal abnormalities, copy number 
variations, rare single nucleotide variants (SNVs), com-
mon polymorphic variations, and epigenetic modifica-
tions; however, only 6–15% of children with ASD have 
well-defined genetic syndromes [3]. Because of the devel-
opment of high-throughput sequencing methods, many 
highly penetrant genetic causes of ASD have been iden-
tified, but the underlying genetic background of 70% of 
cases remains unexplained [4].
Mitochondrial disease (MD) is presently one of the 
most recognized metabolic diseases caused by the failure 
of both nuclear and/or mitochondrial DNA (mtDNA). 
The prevalence of mtDNA mutations responsible for MD 
is 1 in 5000, whereas that of nuclear mutations is 2.9 per 
100,000 cases [5]. Although MD frequently results in a 
spectrum of disorders with multisystemic presentations, 
neurological symptoms are common because tissues with 
high-energy demands, such as neural tissue, are often 
the most strongly affected by mitochondrial dysfunc-
tion. Even though the diagnosis of MD is increasing and 
becoming more frequent, the exact genetic background 
in many cases remains unconfirmed. Mitochondrial dys-
function can be caused by either primary MD or second-
ary mitochondrial damage [6]. Primary MD is because of 
genetic defects in mtDNA or a defect in a nuclear gene 
that is important for mitochondrial function. These 
mutations usually affect proteins involved in reactions of 
oxidative phosphorylation (OXPHOS). However, many 
disorders show similar effects in terms of mitochondrial 
dysfunction, but are elicited by mutations in other genes 
not related directly to normal mitochondrial function [7]. 
In other cases environmental factors, associated disor-
ders or ageing are resulting in secondary alterations.
Several authors have proposed that mitochondrial dys-
function may be one of the most common medical con-
ditions associated with autism [8, 9]. Lombard et al. [10] 
proposed that ASD may be a condition with abnormal 
mitochondrial function. Clinical and biochemical stud-
ies have uncovered an emerging link between mitochon-
drial dysfunction and neurodevelopmental disorders, 
including intellectual disability [11], childhood epilepsy, 
and ASD [9]. Furthermore, mitochondrial dysfunction 
has been associated with some forms of syndromic ASD 
[8, 11]. In many of these studies, biochemical changes, 
such as elevated levels of creatine kinase, lactate, pyru-
vate, carnitine, ammonia, and alanine were detected in 
the serum of patients with ASD [11–14]. In other stud-
ies, altered respiratory chain enzyme activities [15] or 
decreased expression of OXPHOS genes were detected 
in autistic brain [16], findings which indicate abnormal or 
altered mitochondrial function.
Damage to the OXPHOS system was found in individ-
uals with ASD by Napoli et al. [17] and reviewed by Val-
enti et al. [11]. Oliveira et al. [14] found that 7% (7/100) of 
children with ASD, who were clinically indistinguishable 
from other affected children with ASD, exhibited a mito-
chondrial respiratory chain disorder. Weissman et al. [18] 
proposed that defective mitochondrial OXPHOS may be 
an additional underlying pathogenic mechanism in a sub-
set of individuals with autism.
Despite evidence of altered mitochondrial function 
in some individuals with ASD, it is not known whether 
mitochondrial dysfunction is a cause or an effect of 
ASD. Although a mitochondrial subgroup in ASD could 
be identified [19], findings from review articles, such 
as those of Palmieri and Persico [19] and Rossignol and 
Frye [9], found that even in this subgroup the causative 
genetic factor could be identified in a proportion of cases 
(23%). In cases of non-syndromic ASD, mitochondrial 
dysfunction without mtDNA alterations has been fre-
quently observed [8, 9]. In a systematic review and meta-
analysis, Rossignol reported that MD was present in 5% 
of children with ASD [9], and in this ASD/MD subgroup, 
mtDNA abnormalities were found in 23% of patients [9]. 
These findings demonstrate that primary MD may be 
present in a subgroup of children with ASD.
Some studies have reported mtDNA deletions in indi-
viduals with ASD [12, 20–22]. Single mtDNA deletions 
have a role in different paediatric and adult onset pri-
mary MDs such as Kearns–Sayre syndrome, Pearson 
syndrome, and progressive ophthalmoplegia externa [23]. 
Multiple mtDNA deletions occur mostly because of path-
ogenic mutations in genes responsible for intergenomic 
communication; however, they are often related to age-
ing or harmful environmental factors as well because 
mtDNA has a poor DNA repair system [6, 24].
The aim of the present study was to investigate the 
presence of the most common pathogenic mtDNA alter-
ations in patients with ASD and to elucidate the etiology 
of these mtDNA alterations by analysing their co-occur-
rence with both known ASD-associated genes and genes 
responsible for mtDNA maintenance and by comparison 
the targeted NGS data (ASD associated genes and genes 
responsible for mtDNA maintenance) of cases with and 
without mtdel-ASD, patients with primary mitochondrial 
disorders and healthy controls.
Methods
Patients
Detailed clinical examinations consisting of a general 
medical examination and neurological assessment were 
performed. A diagnosis of ASD was made using the 
ADI-R (autism diagnostic interview—revised) and ADOS 
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(autism diagnostic observation schedule). Patients were 
screened for minor physical abnormalities, which were 
selected based on the Méhes Scale [25]. Family history 
and detailed environmental/societal data were collected 
from the first degree relatives of each patient. Any dis-
orders present in the parents as well as environmental 
factors were registered. Written informed consent was 
obtained from the parents of the patient. This study was 
performed in accordance with the Helsinki Declaration 
of 1975 and was approved by the Hungarian Research 
Ethics Committee (44599-2/2013/EKU). The diagnosis of 
ASD was based on the standardized ADI-R in Hungarian, 
which was published by the Autism Foundation (Kapocs 
Publisher), according to the following scores: A  ≥  10 
(social interaction), B ≥ 7 (communication), C ≥ 3 (repet-
itive stereotype manner), D ≥ 1 (abnormal development 
under 36  months). Sixty children with ASD [6 females 
and 54 males, median age = 7 years, interquartile range 
(IQR) = 7.25] were included in our study. Before patient 
selection our ASD patients were screened for Fragile X 
syndrome and only negative cases were included in our 
cohort. Of our 60 patients with ASD, 58 are of European 
descent and 2 are Roma. Our control group for mtDNA 
screening consisted of 60 European adults (26 females 
and 34 males, median age  =  28  years, IQR  =  13.75) 
selected from our biobank [26]. All controls were healthy 
individuals under 45 years of age and free from addiction 
(alcohol, smoking, and drugs). For the interpretation of 
our next generation sequencing (NGS) results, we com-
pared data from the following cohorts: patients with ASD 
and without mtDNA deletion, labelled non-mtdel-ASD, 
(6 males and 1 female, median age = 8 years, IQR = 5.5), 
patients with MD and mtDNA deletion, without ASD (4 
males and 3 females, median age = 18 years, IQR = 19), 
and healthy control individuals (1 male and 5 females, 
median age  =  27  years, IQR  =  2.25). The investigated 
patients and controls were not related. All patients with-
out a mtDNA deletion were considered to have non-syn-
dromic ASD. The study design is illustrated in Table 1.
Genetic analysis
DNA was isolated from peripheral blood samples from all 
participants using the QIAamp DNA blood kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instruc-
tions. To identify single and multiple mtDNA deletions, 
long range PCR was performed as described by Reme-
nyi et al. [27]. MtDNA single and multiple deletions were 
screened with long PCR in 20 μl volume: 20 pmol prim-
ers Fw 5′-TAAAAATCTTTGAAATAGGGC-3′ and Rev 
5′-CGGATACAGTTCACTTTAGCT-3′, 0.2  µl Phusion 
DNA Polymerase (Finnzymes, Vantaa, Finland), 4  µl 
Phusion GC Reaction Buffer (Finnzymes, Vantaa, Fin-
land), 0.4 µl dNTP and 12.4 μl water (qPCR grade water, 
AMBION). PCR program was the following: 98  °C 30  s, 
30 cycles: 98 °C 10 s, 63 °C 10 s, 72 °C 3/8 min, then the 
last synthesis at 72  °C 7  min. Amplificates were visual-
ised by ethidium-bromide (2% agarose) and determined 
with QuantityOne Software (Bio-Rad Corp. Hertford-
shire, UK). The three most-frequent pathogenic mtDNA 
point mutations were screened by PCR–RFLP using a 
GeneAmp PCR System 9700 (Applied Biosystems, MA, 
USA) [20]. The most well-known ASD-associated genes 
[28] and 51 genes responsible for intergenomic com-
munication disturbances (Additional file  1: Table S1) 
were investigated using NGS, which was performed on 
a MiSeq (Illumina, CA, USA) using the TruSight Autism 
Rapid Capture Kit (Illumina, CA, USA) and the SureSe-
lect QXT Kit (Agilent Technologies, CA, USA) according 
to the manufacturer’s instructions. In the intergenomic 
panel, 16/32 samples were multiplexed in one sequencing 
run, whereas in the autism panel 24 samples were multi-
plexed in a single run using the MiSeq reagent kit v2 and 
300 cycles (Illumina, CA, USA). The mean read depth was 
152 × in the intergenomic gene panel and 135 × in the 
ASD-associated gene panel. In both panels, 20 × cover-
age was achieved in a minimum of 90% of target regions. 
Pathogenic and likely pathogenic mutations from NGS 
data were validated by Sanger sequencing, and segrega-
tion analysis was performed within individual families.
Table 1 The design of the study
The investigated cohorts and the performed genetic analysis are shown in the Table 1. NGS testing for intergenomic panel and ASD panel has been performed in the 
cohort of the 10 mtdel ASD cases and in subgroup of 7 non-mtdel ASD cases and a subgroup of healthy controls (N = 6). Patients with primary mitochondrial disease 
(N = 7) served as further control group. All investigated person were Caucasian except 2 non-mtdel ASD cases
ASD autism spectrum disorder, MD mitochondrial disease, mtDNA mitochondrial DNA, IG NGS next generation sequencing for genes responsible for intergenomic 
communication, ASD NGS next generation sequencing for autism associated genes
a The 10 mtdel-ASD cases and 7 non-mtdel ASD were investigated
b 6 cases were investigated
Cohorts M.3243 A > G, m.8993 T > C/G, 
m.8344 A > G
mtDNA deletion IG NGS (51 genes) ASD NGS (101 genes)
ASD cases (n = 60) ✔ ✔ ✔a ✔a
Healthy controls (n = 60) ✔ ✔ ✔b ✔b
mtdel-MD (n = 7) ✔ ✔ ✔ –
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Statistical and bioinformatics analysis
Chi square test with Yates correction/Fisher exact test 
were used to determine significant differences between 
patient and control groups [29]. Raw sequences were 
filtered with Picard tools (version 2.1.0) [30] and quality 
filtered reads were aligned to the hg19 reference genome 
with BWA-mem [31] using default parameters. Vari-
ant calling was performed using GATK HaplotypeCaller 
(version 3.3-0) [32] and VCF files were annotated with 
SnpEff (version 4.1) [33]. We analysed only those vari-
ants that were found in the canonical transcript of the 
gene. To identify potentially causal genetic variations, 
we used VariantAnalyzer, which is an in-house software 
developed by András Gézsi from the Budapest Univer-
sity of Technology and Economics [34]. This software 
application annotates SNPs and short indels with several 
types of annotations, such as their predicted function on 
genes using SnpEff, observed allele frequencies in several 
genomic projects including the 1000 Genomes Project 
and the ESP6500 Project, conservation scores based on 
PhyloP or PhastCons, predicted function of non-synony-
mous SNPs using dbNSFP, and disease associations with 
HGMD and ClinVar. By creating filter cascades based on 
these annotations and other information (e.g., genotypes 
and variant quality annotations), the software can eas-
ily be used to filter the variants through a user-friendly 
graphical interface. Analysis and variant calling of Sure-
Select libraries was performed with SureCall software 
(Agilent, CA, USA). First, we filtered for variants known 
to be disease-causing, using human gene mutation data-
base (HGMD) Professional 2015.1 edition [35]. Second, 
we filtered for rare variants based on the minor allele fre-
quency and frequency of the mutation in our NGS data 
repository. Since large-scale genomic data of the Hun-
garian population is not available, a mutation with a low 
minor allele frequency may also be population-specific. 
We labelled a variant as a rare mutation if it was present 
in one or two samples within our cohort and the minor 
allele frequency in Europeans from the 1000 Genomes 
and ExAC databases was less than 0.5%. It is important 
to note that a limitation of this method is that it may 
exclude identification of founder mutations and disease-
associated polymorphisms. Finally, mutations were prior-
itized based on their predicted effects. Exonic frameshift 
and stop mutations were considered always damaging, 
whereas the effects of missense mutations were predicted 
using Polyphen2, SIFT (Sort Intolerant From Tolerant), 
or MutationTaster (MT).
Results
Sixty children with ASD (6 females and 54 males, median 
age = 7 years, IQR = 7.25) were investigated. In our ana-
lysed cohort of 60 patients, 29 patients were sporadic 
(from simplex families) and their family histories were 
negative for other neurodevelopmental disorders and 
major psychiatric or neurological disorders. The dis-
tribution of the relevant symptoms for mitochondrial 
disorders in mtdel-ASD and idiopathic ASD group are 
shown in Fig.  1. There were some differences between 
ASD cases with and without mtDNA deletion regarding 
the clinical phenotype. Developmental regression, mus-
cle hypotonia, and additional neurological signs were 
most common in the mtdel-ASD cases. Multisystemic 
abnormality appeared also more frequently. Referring to 
seizures no major differences has been observed between 
these two groups. Family history was not available in two 
cases because these children were not living with their 
biological parents. A positive family history was found in 
48% of cases, of which 20 cases (33.3%) had a family his-
tory for psychiatric disorders (bipolar disorder, depres-
sion, and schizophrenia). In four cases (6.7%), visual and 
hearing impairments, ataxia, complex endocrine disor-
ders, or a combination of these factors was noted. The 
co-occurrence of these symptoms is an indicator for MD 
according to mitochondrial disease criteria (MDC) [36]. 
In five cases (8%), we found a positive family history for 
psychiatric disorders and some MDC-related symptoms 
were also noted.
Minor physical anomalies were identified in 44 chil-
dren. All children were diagnosed with ASD based on 
ADI-R, and in most cases, with ADOS as well. We found 
that serum lactate levels and/or the lactate:pyruvate ratio 
supported the presence of mitochondrial dysfunction in 
four patients.
Genetic investigation—mtDNA mutation screening
Mitochondrial deletions were identified in 16.6% (10/60) 
of our patients with ASD. Two children had multiple 
deletions, whereas a single major deletion was detected in 
the range of 2.4–7.9 kb in eight children. Detailed clinical 
and family history data as well as associated phenotype 
of the patients harbouring mtDNA deletions are shown 
in Table  2. An evaluation of clinical phenotype, fam-
ily history, and laboratory data suggested MD in seven 
cases with mtDNA deletion. None of the investigated 
families had a previous diagnosis of primary MD. In all 
cases, the rate of heteroplasmy (HP) was > 20% in blood 
samples (Table 2). In the 60 healthy control individuals, 
a mtDNA deletion was found in two cases. Based on our 
statistical analysis, there was a significant difference in 
the frequency of mtDNA deletions between our ASD and 
control cohorts (χ2 with Yates correction = 4.5; p = 0.03; 
odds ratio  =  5.8; 95% CI 1.21–27.72). Further analysis 
of mtDNA mutational “hotspot” regions (m.3243 A > G, 
m.8993 T > C/G, and m.8344 A > G) did not detect any 
alterations in our ASD cohort.
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Genetic investigation—nuclear DNA mutation screening 
of genes responsible for intergenomic communication
Next, we focused on those patients with mtDNA dele-
tions (mtdel-ASD) and performed nuclear DNA (nDNA) 
mutation screening to investigate genes involved in 
intergenomic communication. In this subgroup, we 
found one rare likely pathogenic variant and one vari-
ant with uncertain significance (VUS). The rare variants 
identified in two patients were both present in only one 
allele, however the mode of inheritance of these disor-
ders is autosomal recessive (Table  3). In Patient 5 (P5), 
the likely pathogenic heterozygous T265I mutation in 
the mitochondrial genome maintenance exonuclease 1 
(MGME1) is responsible for mtDNA integrity [37]. In 
Patient 9 (P9), we found a de novo VUS mutation (Clin-
Var ID203970) in succinate-CoA ligase alpha subunit 
(SUCLG1) in a heterozygous form.
In our cohort of seven patients with MD (without ASD) 
harbouring mtDNA deletions, we found a pathogenic 
rare variants in two case, and rare VUS in five further 
cases (Table  2). In one patient the compound heterozy-
gous state of one pathogenic and one VUS in C10orf2 
gene were detected. In cohorts without MD (patients 
with ASD lacking mtDNA deletion and healthy individu-
als) we found two–two rare VUS in genes responsible for 
intergenomic communications (Table 3).
Comparing the intergenomic NGS panel results for 
our different cohorts, we found no significant difference 
between  mtdel-ASD cases and healthy controls with 
one tailed Fisher exact test (p: 0.4890 odds: 0.5, CI 0.05–
4.97); and mtdel-ASD and ASD without mtDNA dele-
tion groups (p:0.55882, Odds: 0625 CI 0.06–5.96). Likely 
pathogenic variant and VUS were identified in higher 
number in MD patients with mtDNA deletion and with-
out ASD (p =  0.013, Odds: 0.04 CI 0.003–0.5743), in a 
heterozygous form (Table 3).
Genetic investigation—nDNA mutation screening 
of ASD‑associated genes
Using the TruSight Autism NGS panel, we detected rare 
SNVs in 90% (9/10) of our affected children with mtDNA 
deletion. Syndromic ASD was identified in a single case, 
Patient 3 (P3), from our mtdel-ASD cohort. A heterozy-
gous pathogenic mutation in chromodomain helicase 
DNA-binding protein 7 (CHD7) was found in this patient 
as well as a heterozygous mutation of uncertain signifi-
cance in tuberin (TSC2). The CHD7 rare variant regarding 
the ACMG guideline, fulfils the PVS1 and one PS2 crite-
ria [38] and based on this we evaluated it as pathogenic. 
The patient’s phenotype and the family segregation pat-
tern indicated this CHD7 mutation as a de novo mutation 
resulting in CHARGE syndrome (OMIM 214800) [39].
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In Patient 8 (P8), we found a pathogenic nonsense 
mutation in 7-dehydrocholesterol reductase (DHCR7), 
which was present in only one allele.
In Patient 2 (P2) a rare mutation was detected in autism 
susceptibility candidate 2 (AUTS2), which previously was 
associated with syndromic ASD form. The significance of 
the missense mutation identified in our study is uncer-
tain; during segregation analysis the same mutation was 
present in the healthy mother, however we do not know 
exactly the penetrance of the genetic defects of AUTS2. 
This rare AUTS2 variant coexisted with a rare variant in 
retinoic acid induced gene 1 (RAI1) (Table 4).
Using in silico analysis, alterations of uncertain sig-
nificance were detected in ASD-associated genes in 60% 
(6/10) of the mtdel-ASD cases and 71% (5/7) of non-
mtdel-ASD cases (Table  4). In the six control individu-
als only four rare VUS were detected in genes associated 
with ASD. The rare variant in zinc finger protein 804A 
(ZNF804A) was found in two healthy controls, indicating 
a variant that is likely population-specific (Table 4).
Detailed phenotype of a patient with mtDNA deletion 
and CHARGE syndrome (CHD7 mutation)
An 11-year-old male patient (P3) had multiple congeni-
tal anomalies, such as coloboma of the eyes, oxyceph-
aly, epicanthus, convergent strabismus, mild bifid nose/
broad nasal tip, low settled cup ears, mild facial asymme-
try, dental dysgenesis, asymmetric chest, macroglossia, 
cryptorchidism, testicular hypoplasia, and atrial septal 
defect. He began walking at 3  years of age and suffers 
from obsessive hand movements, erratic behavior, and 
sleep disturbance. Aside from his developmental abnor-
malities, neurological investigation detected pes varus, 
severe visual impairment, bilateral ptosis, chewing diffi-
culties, mild atrophy and weakness in the distal muscles 
of the extremities, and truncal ataxia. High lactate lev-
els were detected in both serum and cerebrospinal fluid, 
and decreased levels of serum melatonin, calcium, and 
vitamin D3 were measured. A brain MRI detected hypo-
plastic vermis and transverse sinus on the right side. An 
EEG found generalized irritative signs, and VEP found 
an increased P100 on the left side. Brainstem auditory 
evoked potentials was normal. Family history identified 
arrhythmia, diabetes mellitus, and colon polypomatosis 
on the maternal side, and diabetes mellitus, arrhythmia, 
and dementia on the paternal side.
Detailed phenotype of a patient with congenital 
cytomegalovirus infection and mtDNA deletion
The 5-year-old female patient (P8) was born at a ges-
tational age of 39  weeks by Caesarean section with a 
birth weight of 3000 g. The pregnancy was complicated 
with a partial placental abruption at 11 weeks. Evidence 
of prolonged neonatal jaundice, highly elevated liver 
enzymes, low prothrombin level, and high IgM and IgG 
type anti-cytomegalovirus (CMV) antibodies led to the 
diagnosis of a congenital CMV infection-induced hepatic 
lesion. She had congenital sensorineural hearing loss, 
mild myopathic facies, mild ptosis, and atopic facial der-
matitis. A brain MRI identified several T2 hyperintense 
supratentorial lesions (5–10  mm in size), which were 
suggested to have an infectious etiology. A heterozygous 
nonsense mutation in DHCR7 and a major large single 
deletion in mtDNA were found. The healthy mother also 
harbours the detected heterozygous mutation. Choles-
terol and 7-dehydrocholesterol levels of the child are in 
the normal range. Homozygous or compound heterozy-
gous mutations in DHCR7 result in Smith–Lemli–Opitz 
(SLOS) syndrome, which is an autosomal recessive dis-
ease. However, human CMV infection may lead to altered 
mitochondrial biogenesis [40]. We believe that this case 
demonstrates a direct interaction between genetic and 
environmental risk factors in some forms of ASD.
Discussion
In this study, we provide for the first time a comprehen-
sive genetic analysis of patients with ASD that inves-
tigates co-occurrence of the most frequent mtDNA 
alterations, intergenomic communication disturbances 
(51 genes), and 101 genes previously associated with 
ASD. We found co-occurrence of mtDNA deletions with 
ASD-associated genetic alterations, which supports the 
previous observation that mitochondrial alterations are 
frequently associated with ASD. In one patient with ASD 
(P3), we found a mtDNA deletion with CHARGE syn-
drome caused by a de novo mutation in CHD7. These 
genetic alterations in P3 were also accompanied by a 
TSC2 mutation of uncertain significance. Autistic symp-
toms are present in approximately 30% of patients with 
CHARGE syndrome [39], and lactic acidosis is a rare 
alteration. Based on the phenotype, we conclude that 
the driving genetic alteration in this patient is the CHD7 
mutation, and the mitochondrial gene defect may not 
be the true causative factor in the etiology of the dis-
ease; however, CHD7 function is strongly ATP-depend-
ent [41]. In addition, the associated heterozygous TSC2 
mutation is likely a modifying gene. CHD7 is a member 
of the chromo-domain helicase DNA-binding (CHD) 
protein family and plays a role in transcription regula-
tion through chromatin remodelling. Mutations in TSC2 
are known to cause one syndromic form of ASD; how-
ever, our patient did not develop the classic symptoms 
of tuberous sclerosis until recently. TSC2 mutations 
may induce activation of mTORC1 leading to increased 
mtDNA expression and mitochondrial density. mTOR is 
a Ser/Thr kinase that forms complexes with numerous 
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protein partners to regulate cell growth, mitochondrial 
membrane potential, and ATP synthetic capacity [42].
In Patient 8, we found that the mtDNA deletion was 
accompanied by a heterozygous pathogenic DHCR7 muta-
tion and a rare variant of uncertain significance in NHS 
actin remodelling activator (NHS). DHCR7 catalyses cho-
lesterol production from 7-dehydrocholesterol, and defects 
in this protein cause SLOS. Furthermore, a high 7-dehydro-
cholesterol level results in mitochondrial dysfunction [43]. 
However, the significance of a heterozygous mutation in 
this gene is not known. We hypothesize that in the case pre-
sented here the co-occurrence of the DHCR7 heterozygous 
mutation and CMV infection may play a role in changes of 
mitochondrial biogenesis and in the pathogenesis of autis-
tic features. The patient was tested for SLOS; both serum 
cholesterol and 7-dehydrocholesterol levels were normal, 
which rules out the presence of typical SLOS.
Evidence of mitochondrial dysfunction in ASD was 
first described 19 years ago [10]. Currently, it is the most 
common metabolic abnormality known in ASD with a 
prevalence of 7.2% [14]. In a subgroup of the CHARGE 
(Childhood Autism Risk from Genes and Environment) 
study, decreased NADH activity was found in lympho-
cytes in 8 of 10 cases. In this cohort, only 2 of the 10 
patients had mtDNA deletions and 5 patients had altered 
mtDNA copy numbers [12]. However, the genetic back-
ground was not clarified in 79% of the patients with 
ASD-MD [9]. Therefore, the possibility of secondary 
damage to mitochondria cannot be excluded. A small 
pilot study examining 12 patients with ASD described 8 
mitochondrial deletions [21], which could be the result 
of intergenomic communication disturbances, environ-
mental factors, or other gene–gene interactions. As is the 
case for many other disorders, it is still not clear whether 
the detected mitochondrial dysfunction in ASD is a pri-
mary or secondary event either having a key role in dis-
ease pathogenesis or is simply a downstream effect.
In our study, mtDNA deletions were identified in 16.6% 
of evaluated patients with ASD. During mtDNA hotspot 
screening and NGS analysis, no concomitant primary 
MD was detected. To examine whether mtDNA deletion 
is a primary or secondary event in ASD in our cohort, we 
used different comparison groups to screen the nDNA 
background of the mtDNA deletion. Pathogenic or likely 
pathogenic variants were detected in both mtdel-ASD 
and MD without ASD cases, all in heterozygous form. 
A high number of VUS in intergenomic communica-
tion genes were detected in the MD without ASD cohort 
(4/6), and a few rare variants were identified in patients 
with ASD that lacked mtDNA deletion and in healthy 
controls (Table 3). Homozygous or compound heterozy-
gous mutations in MGME1 and SUCLG1 have been pre-
viously correlated with severe early-onset mitochondrial 
disorders (OMIM 615084, OMIM 245400) [44]. The 
importance of the presence of heterozygous mutations is 
not well understood. It is known in some genes respon-
sible for intergenomic communications heterozygous 
mutations may result in a less severe phenotype than that 
found with the homozygous form [45].
The question has also been raised whether patients with 
MD and ASD symptoms have special characteristics. In 
a study by Rossignol and Frye [9], a cohort of ASD/MD 
children were compared to two comparison groups: chil-
dren with general ASD and children with general MD. In 
the ASD/MD group, increased lactate and pyruvate levels, 
seizures, motor delays, and gastrointestinal abnormalities 
were significantly more prevalent compared to children 
with general ASD. A more balanced male:female ratio was 
also detected in the ASD/MD group [9]. Our results con-
firm the observations by Rossignol and Frye; however, in 
our ASD cohort with mtDNA deletion, elevated lactate 
levels and/or an elevated lactate:pyruvate ratio were found 
in only four cases, whereas most of our ASD patients with 
mtDNA deletion had symptoms common to MD, such as 
hypoacusis, muscle weakness, hypotonia, delayed motor 
development, and movement disorder (Fig.  1). Signifi-
cant difference between mtdel-ASD and non-mtdel-ASD 
group was found regarding clinical phenotypes (devel-
opmental regression, muscle hypotonia, additional neu-
rological signs and multisystemic alterations were more 
common in cases mt-delASD). Interestingly, the phe-
notypes of classic mitochondrial deletion syndromes, 
such as Pearson syndrome, progressive ophthalmoplegia 
externa, and Kearns–Sayre syndrome, were not detected 
in any of our patients. The family histories of mtdel-ASD 
children in our cohort differed from the family histo-
ries of the ASD cohort without a mtDNA deletion, since 
various psychiatric disorders were common among fam-
ily members of mtdel-ASD cases both on maternal and 
paternal side. However none of the parents reached the 
MDC scoring cut-off value for definitive MD, which could 
not be independently verified because none of the family 
members agreed to perform muscle biopsy. MtDNA dis-
orders are usually inherited maternally, however single 
mtDNA deletions are considered sporadic events with 
low inheritance risk, whereas multiple mtDNA deletions 
are the result of primary nuclear defects in genes respon-
sible for mtDNA maintenance or nucleoside metabolism 
and follow Mendelian inheritance patterns [46].
Mitochondrial haplogroups were also investigated in 
association with ASD. Chalkia et al. found that individu-
als with European haplogroups designated I, J, K, X, T 
and U (55% of the European population) had significantly 
higher risks of ASD compared to the most common 
European haplogroup, HHV. Asian and Native American 
haplogroups A and M also were at increased risk of ASD 
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[47]. In Hungary it is not rare that a person has ancient 
European haplotype such as T, K, and U haplotype, and 
rarely Asian haplotype such as B can occur as well. In 
some Hungarian patients the mtDNA deletion was coex-
isting with ancient haplotype [48].
In 90% (9/10) of children from the mtdel-ASD cohort, 
we found rare SNVs in ASD-associated genes (Table 4). 
A rare mutation was detected in AUTS2 in which dele-
tions are inherited in an autosomal dominant manner 
and are associated with neurological symptoms including 
intellectual disability and developmental delay [49]. In a 
modest study of 13 cases of ASD associated with AUTS2 
alterations, only one patient had a nonsense mutation; all 
the other patients had a deletion [49]. The significance of 
the missense mutation identified in our study is uncer-
tain (her mother harbours the mutation as well); how-
ever, clinical symptoms of the patient correlate with the 
phenotype of previously published AUTS2 mutations. 
This rare AUTS2 variant coexisted with a rare variant 
in retinoic acid induced gene 1 (RAI1). The gene–gene 
interaction of these two alterations are hypothesized.
In addition, we found that patients had mutations of 
uncertain significance in forkhead box P2 (FOXP2), RAI1, 
phosphodiesterase 10A (PDE10A), katanin catalytic sub-
unit A1 like 2 (KATNAL2), and reelin (RELN). Most of 
these genes play a role in cell regulation, signal transduc-
tion, and various signalling pathways, which could influ-
ence mitochondrial function. FOXP2 is an evolutionarily 
conserved transcription factor that regulates the expres-
sion of a variety of genes. Mutations in this gene cause 
speech-language disorder 1 (OMIM 602081), which 
is also known as autosomal dominant speech and lan-
guage disorder with orofacial dyspraxia [50]. RAI1 acts 
as a transcriptional regulator of chromatin remodel-
ling by interacting with basic transcriptional machinery 
[51]. RAI1 deletion is associated with Smith–Magenis 
syndrome, whereas duplications are associated with 
Potocki–Lupski syndrome [52]. Several heterozygous 
mutations are also associated with Smith–Magenis syn-
drome [53]. In our case, we found that the typical symp-
toms of Smith–Magenis syndrome were not present. 
Mutations in PDE10A can affect cyclic nucleotide con-
centrations. This phosphodiesterase selectively catalyzes 
the hydrolysis of 3′ cyclic phosphate bonds in cAMP and/
or cGMP. The phosphodiesterase family of proteins regu-
lates cellular levels, localization, and duration of action 
of these second messengers by controlling the rate of 
their degradation. In addition, phosphodiesterases are 
involved in many signal transduction pathways and are 
implicated in the pathogenesis of bipolar disorder [54].
Mitochondrial dysfunction may be associated with 
several forms of syndromic ASD, but is also frequently 
related to non-syndromic cases [8, 9]. During our 
comprehensive analysis, we found examples of both but 
in most cases we did not find the causative genetic muta-
tion that accounts for the mitochondrial dysfunction. 
In the examined children from the general ASD cohort 
(without mtDNA deletion), we found several VUS, 
most of which were identified in genes without previ-
ous correlation to mitochondrial dysfunction. Based on 
our findings, we conclude that the detected mitochon-
drial DNA deletions in patients with ASD in our cohort 
are a secondary effect. By investigating the most com-
mon mtDNA alterations and the most common nuclear 
genes responsible for intergenomic communications, we 
did not identify the clear genetic etiology in most of our 
cases. Therefore, further investigation and characteriza-
tion is warranted.
Limitations
We identified certain limitations in our study. We focused 
our investigation to analyse mutational hotspots and 
large mtDNA deletions and did not sequence the entire 
mitochondrial genome. The mtDNA mutations were 
analysed from blood samples; postmitotic tissue was not 
available. The used long PCR method detects deletions 
in the mtDNA with high sensitivity and low specificity. 
Deletions under 10% of heteroplasmy could be missed 
due to technical barrier, overestimation of the HP ratio 
is not expected. The detection of mtDNA deletion from 
NGS data will be in the future a new perspective, but 
today it is not in the everyday praxis. We used targeted 
NGS panels comprised of the most important genes 
associated with intergenomic communication and ASD. 
However, these panels do not include all currently associ-
ated genes and the number of these genes is continuously 
increasing. Finally, our healthy control group was older 
than our ASD cohort and had different gender ratios. 
However, we felt that ethically it was not appropriate to 
obtain biomaterial from healthy children for genetic test-
ing. Since somatic mtDNA deletion may occur in asso-
ciation with ageing, and we detected the mtDNA deletion 
less frequently in the control group it had no impact on 
our data. Mitobreak Database [55] supports or presump-
tion since deletion were present mostly only aged healthy 
controls, otherwise they were associated or to sporadic 
primary mitochondrial disorders (single deletion) or to 
disorders due to intergenomial gene alterations (multiple 
deletions).
Conclusions
The aim of our study was to gain a better understand-
ing of mitochondrial dysfunction in autism. We found 
that mtDNA alterations were more common among our 
cohort of patients with ASD than in control individu-
als. In addition, we found that the mtDNA deletion was 
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usually not the single genetic alteration identified in ASD, 
but co-occurred in both syndromic and non-syndro-
mic forms of ASD with either ASD-associated genetic 
risk factors and/or alterations in genes responsible for 
intergenomic communication. Our findings indicate a 
very complex pathophysiology of ASD in which mito-
chondrial dysfunction is not rare and can be caused by 
mtDNA deletion, which may be considered as de novo 
mutations or the consequence of the alterations of the 
causative culprit genes for autism or genes responsible 
for mtDNA maintenance.
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